SB 248 Utah Senate · 2025 General Session

Controlled Substances Amendments

SB 248 amends Utah law to allow specific healthcare systems (like university-affiliated cancer centers or large non-profit hospitals) to develop treatment programs using psilocybin or MDMA under strict conditions. It permits these providers to use such substances only when they are in FDA Phase 3 clinical trials, require patient reports on outcomes and side effects by 2027, and prohibit use for anyone under 18. The bill also automatically aligns Utah’s classification of certain psilocybin with any federal rescheduling change. These provisions apply only to licensed healthcare providers meeting the bill’s criteria, not to general public use.

Issues: ✓ Healthcare

Bill status in committee 1 of 4 stages cleared

Introduction

Feb 2025

Committee Review

Floor Vote

Governor

Introduced Feb 11, 2025 Last action Mar 8, 2025

Maddy AI version diff · 1 comparison

What changed between versions

Introduced → Substitute #1 · 4 edits

MODERATE

This bill substitutes a new version of SB 248 that significantly narrows the eligibility criteria for psilocybin and MDMA behavioral health treatment programs. The changes remove requirements for large healthcare systems and higher education affiliations, replacing them with more accessible options like cancer treatment centers and licensed psychiatrists. Additionally, the bill extends the repeal date for the new behavioral health treatment section from July 1, 2027 to July 1, 2029, and modifies supervision requirements from direct to indirect oversight.

Scope change

The bill's scope shifted from requiring large healthcare systems or higher education affiliations to include smaller providers like cancer treatment centers and individual psychiatrists, making psilocybin and MDMA treatment more accessible to a broader range of healthcare providers.

ELIGIBILITY

Replaced requirements for large healthcare systems (15+ hospitals) and higher education affiliations with new options including cancer treatment centers with palliative care providers and licensed psychiatrists with clinical trial experience.

REQUIREMENT

Changed supervision requirements from 'direct' to 'indirect' supervision and control for patients using psilocybin or MDMA under the new behavioral health treatment program.

TIMELINE

Extended the repeal date for the behavioral health treatment section from July 1, 2027 to July 1, 2029, giving the program more time before it expires.

DEFINITION

Modified the definition of 'Health care provider' to include cancer treatment centers with palliative care experience and licensed psychiatrists with clinical trial experience, replacing the previous requirements for large healthcare systems.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Feb 28, 2025

Upper · Passed

Senate Comm - Favorable Recommendation

upper

Feb 26, 2025

Committee

Senate/ to standing committee

upper

Feb 11, 2025

Introduced

Senate/ 1st reading (Introduced)

upper

1 primary · 0 co-sponsors